Tharmalingam Senthuran, Flemming Jennifer, Richardson Harriet, Hurlbut David, Cleary Sean, Nanji Sulaiman
From the Department of Surgery, Queen's University, Kingston, Ont. (Tharmalingam, Nanji); the Department of Medicine, Queen's University, Kingston, Ont. (Flemming); the Department of Public Health Sciences, Queen's University, Kingston, Ont. (Flemming, Richardson); the Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ont. (Hurlbut); and the Department of Surgery, Mayo Clinic, Rochester, Minn. (Cleary).
Can J Surg. 2022 Jan 11;65(1):E16-E24. doi: 10.1503/cjs.019719. Print 2022 Jan-Feb.
The extent of resection required in advanced gallbladder cancer is controversial. We aimed to describe the management and outcomes in patients with resected stage T2 and T3 gallbladder cancer.
In this population-based study, all T2 and T3 gallbladder cancer cases from Jan. 1, 2002, to Mar. 31, 2012, were identified from the Ontario Cancer Registry; pathology reports were linked and abstracted. The type of resection was classified as extended (cholecystectomy + liver resection, with or without bile duct resection) or simple (cholecystectomy only). We used Kaplan-Meier survival analysis to model time to death and evaluated factors associated with overall survival using the Cox proportional hazards regression model.
A total of 370 patients were included, 232 with T2 disease and 138 with T3 disease. The proportions who underwent extended resection were 24.1% (56/232) and 37.0% (51/138), respectively. The unadjusted 5-year overall survival rates for simple and extended resection were 39.7% and 49.5%, respectively, for T2 disease ( = 0.03), and 13.5% and 22.8%, respectively, for T3 disease ( = 0.05). In adjusted analysis, extended resection significantly improved overall survival among patients with T2 disease (hazard ratio [HR] 0.51, 95% confidence interval [CI] 0.30-0.97), whereas higher grade of differentiation, presence of lymphovascular invasion and positive lymph nodes led to worse survival. Extended resection was not associated with improved survival in the T3 group; however, in subgroup analysis stratified by lymph node status, a trend toward improved overall survival with extended resection was seen in node-negative patients (HR 0.20, 95% CI 0.03-1.06).
Extended resection improved overall survival in T2 disease regardless of nodal status but appeared most beneficial in node-negative T3 disease. The finding that extended resection was offered only to a small proportion of eligible patients highlights the need for improved knowledge translation at national surgical meetings.
晚期胆囊癌所需的切除范围存在争议。我们旨在描述接受手术切除的T2和T3期胆囊癌患者的治疗情况及预后。
在这项基于人群的研究中,从安大略癌症登记处识别出2002年1月1日至2012年3月31日期间所有T2和T3期胆囊癌病例;对病理报告进行关联和提取。切除类型分为扩大切除(胆囊切除术+肝切除术,伴或不伴胆管切除术)或单纯切除(仅胆囊切除术)。我们使用Kaplan-Meier生存分析对死亡时间进行建模,并使用Cox比例风险回归模型评估与总生存相关的因素。
共纳入370例患者,其中T2期疾病患者232例,T3期疾病患者138例。接受扩大切除的比例分别为24.1%(56/232)和37.0%(51/138)。T2期疾病单纯切除和扩大切除的未调整5年总生存率分别为39.7%和49.5%(P = 0.03),T3期疾病分别为13.5%和22.8%(P = 0.05)。在多因素分析中,扩大切除显著改善了T2期疾病患者的总生存(风险比[HR] 0.51,95%置信区间[CI] 0.30 - 0.97),而高分化程度、存在淋巴管侵犯和阳性淋巴结导致生存较差。扩大切除与T3组生存改善无关;然而,在按淋巴结状态分层的亚组分析中,在淋巴结阴性患者中观察到扩大切除有改善总生存的趋势(HR 0.20,95% CI 0.03 - 1.06)。
扩大切除改善了T2期疾病患者的总生存,无论淋巴结状态如何,但在淋巴结阴性的T3期疾病中似乎最有益。扩大切除仅应用于一小部分符合条件的患者这一发现凸显了在全国外科会议上改善知识传播的必要性。